Fc-independent Phagocytosis: Implications for IVIG and other Therapies in Immune-mediated Thrombocytopenia

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)

Volume 16, 3 Issues, 2016

Download PDF Flyer

Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Garry X. Shen
University of Manitoba
Winnipeg, MB

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Fc-independent Phagocytosis: Implications for IVIG and other Therapies in Immune-mediated Thrombocytopenia

Cardiovascular & Hematological Disorders-Drug Targets, Volume 12 (E-pub ahead of print)

Author(s): June Li, Dianne E. van der Wal, Lingyan Zhu, Brian Vadasz, Elisa K. Simpson, Conglei Li, Michelle Lee Webster, Guangheng Zhu, Sean Lang, Pingguo Chen, Qingshu Zeng and Heyu Ni.

Affiliation: Canadian Blood Services and Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, University of Toronto, Room 420, LKSKI – Keenan Research Center, 209 Victoria Street, Toronto, Ontario, Canada M5B 1W8


Phagocytes were first described by Dr. Metchnikoff in 1873. The roles of phagocytes in innate and adaptive immunity have been well established to date, although the molecular mechanisms involved in initiating phagocytosis (through Fc or other receptors) remain to be further explored. Phagocytes in the reticuloendothelial system, particularly macrophages, have been implicated in the clearance of senescent blood cells. The destruction of these cells may be primarily mediated via an Fc-independent pathway. Fc-independent phagocytosis may also play an important role in platelet clearance, including in autoimmune thrombocytopenia (ITP), and in clearance of platelet-rich emboli detached from sites of vascular injury. In ITP, the two major platelet auto-antigens have been located on glycoprotein (GP)IIbIIIa and the GPIb complex. It has been demonstrated that anti-GPIb antibodies, in contrast to anti-GPIIbIIIa, can induce thrombocytopenia in an Fc-independent manner. We further demonstrated in an animal model that intravenous IgG (IVIG) is unable to ameliorate thrombocytopenia caused by most anti-GPIb antibodies, despite its efficacy in anti- GPIIbIIIa-mediated thrombocytopenia. Our data was supported by subsequent retrospective studies with ITP patients by several independent groups. Most recently, we found that anti-GPIb-mediated ITP was also resistant to steroid therapy and that platelet activation and apoptosis induced by anti-GPIb antibodies may be involved in the Fc-independent platelet clearance. Therefore, identification of antibody specificity in patients, e.g. anti-GPIIbIIIa (Fc-dependent) versus anti-GPIb (Fc-independent), may be important for therapies against ITP, as well as other immune-mediated thrombocytopenias.


GPIIbIIIa and GPIb complex, Intravenous IgG, Phagocytosis, Platelets, Thrombocytopenia, Thrombosis.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
First Page: 1
Last Page: 9
Page Count: 9
Global Biotechnology Congress 2016Drug Discovery and Therapy World Congress 2016

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science